|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
COX-2 was expressed in DCAMKL1-positive tuft cells in Cdx2- and DCAMKL1-transgenic mouse stomachs, whereas the Sox9 transcription factor was ubiquitously expressed in gastric carcinomas, including COX-2-positive cells.
|
25228975 |
2014 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These results indicate that Cox-2 is widely expressed in human bladder carcinomas and that the role of Cox-2 inhibition in bladder cancer should be further studied.
|
11827414 |
2001 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
This suggests that COX-2 over-expression may be an early event in breast cancer aetiology permitting clones within the normal epithelium to evade apoptosis, to increase their numbers and perhaps acquire further changes that promote the formation of hyperplasias, and eventually carcinomas.
|
15642177 |
2005 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
COX-2 gene product was evaluated immunohistochemically in 30 healthy persons, in 22 patients with dysplastic lesions without previous or concomitant carcinomas, and in 29 patients with oral carcinomas.
|
12747975 |
2003 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
However, COX-2 mRNA was strongly expressed in the well-differentiated carcinomas compared to those of normal thyroid tissue and follicular adenoma.
|
16362262 |
2006 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our results suggest that overexpression of COX-2 is sufficient to cause hyperplasia and carcinomas in the urinary bladder.
|
15753378 |
2005 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
COX-2 indices were significantly higher in gastric carcinoma tissues with deep invasion; indices for pT1, pT2, pT3, and pT4 carcinomas were 0.8 +/- 0.3, 2.8 +/- 0.5, 4.3 +/- 1.0, and 8.8 +/- 5.5, respectively (P < 0.05).
|
11346869 |
2001 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our data show that the MVD corresponds to the COX-2 overexpression in gallbladder carcinomas.
|
17177652 |
2006 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Moderate or strong epithelial COX-2 was present in 25% of hamartomas, including two hamartomas with dysplastic changes, and 64% of carcinomas.
|
12912958 |
2003 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
COX2 overexpression has been detected in up to 90% of colon carcinomas, and its downregulation inhibits polyp formation.
|
19468846 |
2009 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Active caspase-3, ssDNA, p53, Bax and COX-2 were more frequently observed among high grade and higher stage (> or =T2) carcinomas compared with low grade and lower stage (T1) tumours.
|
20025478 |
2010 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
There is now increasing evidence that a constitutive expression of COX-2 plays a role in development and progression of malignant epithelial tumors.
|
11196178 |
2001 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The mRNA copy numbers for COX-2 were determined in 18 infiltrating carcinomas using quantitative RT-PCR and TaqMan methodology.
|
12740157 |
2003 |
|
Carcinoma
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
We investigated 5 gastric cancer cell lines and 58 primary gastric carcinomas for the presence of promoter hypermethylation in cox-2 gene.
|
12684668 |
2003 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
COX-2 protein expression was found in all carcinomas under analysis.
|
15958546 |
2005 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
We observed a positivity for COX-2 in 72.1% of PIN and in 44.7% of prostate carcinomas with an overexpression of COX-2 in prostate cancer and PIN compared to benign prostatic tissue (P < 0.0005).
|
17265445 |
2007 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
COX-2 expression was evaluated through immunohistochemical and mRNA analysis in carcinomas, adenomas, and healthy mucosa from six patients carrying germ line biallelic MYH mutations.
|
16103460 |
2005 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Recent studies have shown overexpression of cyclooxygenase 2 (COX 2) and 5-lipoxygenase (5-lipox) in exocrine pancreatic carcinomas, suggesting a potential role of the arachidonic acid (AA) cascade in the regulation of this cancer type.
|
11238189 |
2001 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The ratio of tumor:paired normal mucosa of mRNA expression of ldlr and of cox-2 was measured in specimens taken during colonoscopy. ldlr and cox-2 transcripts were apparent in 11 of 11 carcinomas.
|
10471521 |
1999 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
COX-2 expression was comparable in gastric stump carcinomas and conventional gastric carcinomas and localized primarily to the cytoplasm of the neoplastic cells.
|
11793368 |
2002 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
COX-2 expression induces carcinogenesis and is thought to be an adverse prognostic factor in gastric carcinomas while the prognostic value of DNA mismatch repair (MMR) is still controversial.
|
27854106 |
2017 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Such directed apoptosis could eventually serve as a treatment for an entire class of Cox-2-overexpressing carcinomas.
|
12900768 |
2003 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
These results suggest that larger carcinomas produce more COX-2 to support their own growth and that COX-2 inhibitors may be effective agents of carcinoma growth suppression.
|
9809985 |
1998 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, PPARgamma protein was not detected in all of the eight carcinomas in which COX-2 protein was detected, suggesting that expression of PPARgamma and COX-2 was in a reciprocal relationship.
|
15266333 |
2004 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
There was a marked increase in COX-2 mRNA levels in 12 of 14 carcinomas (86%) compared with paired normal mucosa.
|
7926468 |
1994 |